Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
FiercePharma
Immunomedics finally wins its blockbuster FDA nod for Trodelvy in triple-negative breast cancer
Also known as sacituzumab govitecan, the drug won accelerated FDA nod as a third-line treatment for metastatic triple-negative breast cancer more than a month ahead of…
El Pais
Covid-19 damages pharmaceutical companies on the Stock Exchange and cools mergers
In the worst global stock market crisis in decades, the 600 largest laboratories left 452,000 million dollars (418,000 million euros) in their stock volume in the first…
Neue Zürcher Zeitung
When does the desired vaccine come? Pharmaceutical companies are facing a major test
Last year, industry-wide research and development spending was estimated at $ 180 billion, according to evaluations by market research firm Evaluate Pharma. For…
PMLive
Kyowa Kirin pays $100m upfront for MEI’s blood cancer drug
They are predicted to outsell Zydelig by 2024, according to 2018 EvaluatePharma figures, which estimate Aliqopa will be a $572m product in that year, with Copiktra making…
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
FiercePharma
The top 10 drugs by sales increase in 2020
Thanks to the team at EvaluatePharma and its Vantage 2020 Preview report, we here at FiercePharma have compiled a list of top 10 drugs by estimated sales increase in…
El Pais
Drugs Against HIV, Ebola, Flu, or Arthritis: Labs Trying to Stop Coronavirus
Currently, 196,000 infected have been recruited to participate in 236 studies, according to a report by the consultant Evaluate Pharma.
PMLive
Pfizer gets Array deal payoff as FDA approves Braftovi
EvaluatePharma has estimated that Array’s drugs will make $1.2bn in revenue by 2024, with around two-thirds of that total ($700m) coming from the CRC indication.
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Pharmaceutical Executive
Adapting Biopharma Launches in the COVID-19 Landscape
There are approximately 156 anticipated US launches of biotech or pharmaceutical (biopharma) therapies in 2020, including NMEs, NDAs and biosimilars. Of these, 52 are…
